Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The firm's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Follow-Up Questions
Qui est le CEO de Haleon PLC ?
Mr. Brian Mcnamara est le Chief Executive Officer de Haleon PLC, il a rejoint l'entreprise depuis 2022.
Quelle est la performance du prix de l'action HLNCF ?
Le prix actuel de HLNCF est de $4.71, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Haleon PLC ?
Haleon PLC appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de Haleon PLC ?
La capitalisation boursière actuelle de Haleon PLC est de $41.9B
Est-ce que Haleon PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 20 analystes ont établi des notations d'analystes pour Haleon PLC, y compris 8 achat fort, 9 achat, 8 maintien, 1 vente et 8 vente forte
